Linking these four molecular tumour subgroups to existing FIGO classifications is problematic, and not straight-forward since there is some overlap in these molecular markers for type 1 and type 2 EC [62,71], but in general TP53 mutations are more frequently associated with type 2 EC [serous carcinoma (59–93%), carcinosarcoma (44–91%) and clear cell carcinoma (28–46%)] than with type 1 EC (5–14%) (Figure 3B) [71]. This evidence concerns the gene TP53 and neoplasm.